title: CYP2D6 genotype predicts tamoxifen side effects but not cancer-free or survival benefits in postmenopausal ER+ and/or PgR+ breast cancers.
authors.affiliation: Division of Cellular & Gene Therapies, Center for Biologics Evaluation & Research, US FDA, 9000 Rockville Pike, Bethesda, MD 20892, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Catalano
authors.forename: Troy B
authors.initials: TB
authors.lastname: Hawkins
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.forename: Ansar
authors.initials: A
authors.lastname: Jawaid
authors.forename: Jayne C
authors.initials: JC
authors.lastname: Fox
authors.forename: Huixiao
authors.initials: H
authors.lastname: Hong